Short-term traders should expect downward pressure as delisting risk reprices the stock. Monitor for the compliance plan submission by July 28, 2026; failure to file by November 16, 2026 could result in suspension and eventual delisting. Positive resolution (timely filing) would likely reverse the bearish sentiment, but near-term catalysts are absent.
Price Chart
Executive Summary
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure period to submit a compliance plan, with a potential 180-day extension. For a $29M market cap company already trading on the Nasdaq Capital Market, this increases delisting risk and undermines investor confidence in timely financial reporting.
Key Facts
- Celularity received a Nasdaq notification on May 27, 2026 for failure to timely file its Q1 2026 10-Q (Rule 5250(c)(1)).
- The company has 60 days (until July 28, 2026) to submit a compliance plan; if accepted, it may receive up to 180 additional days (until November 16, 2026) to file.
- Nasdaq stated the notification has no immediate impact on CELU trading, which continues on the Nasdaq Capital Market.
- The company has a $29M market cap and a history of delayed filings, compounding execution risk.
- Cross-filing actuarial verdicts show press-activist + press-offering and press-8k + press-activist combos are amplifiers, suggesting elevated market reaction to Nasdaq-delinquency news in this context.
Financial Impact
No specific financial impact stated; late filing risk adds uncertainty and potentially elevates cost of capital or triggers debt/equity covenants. For a micro-cap, the delisting scare alone can pressure the stock.
Risk Factors
- Potential Nasdaq delisting if the 10-Q is not filed within the extension period; delisting would severely impair liquidity and equity value.
- Cross-filing scores suggest past high-impact events on this segment have symmetric downside (μ_l -35.5% at score=7), so bearish sentiment with score 6 is appropriate given the asymmetric risk.
- No quantitative financial data (revenue, EPS, cash) is provided in the release, making it impossible to assess underlying business health.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303835 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.9110 (+27.70%) |
Sep 30, 2026 26d ago | Press Release | $1.35 | awaiting T+60 | — | $0.9110 (−32.52%) |
Sep 29, 2026 26d ago | 8-K | $1.35 | awaiting T+60 | — | $0.9110 (−32.52%) |
Sep 28, 2026 28d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.9110 (+34.93%) |
Sep 28, 2026 28d ago | 8-K | $1.40 | awaiting T+60 | — | $0.9110 (+34.93%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.9110 (−30.98%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.9110 (−34.93%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.9110 (−3.48%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.9110 (−32.68%) |
Jun 30, 2026 16w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.9110 (−52.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers